1 min read.Updated: 25 Sep 2020, 06:42 AM ISTReuters
Novavax is among global drugmakers racing to develop a vaccine for covid-19, for which there are no current treatments or vaccines approved
Novavax said it could produce up to 2 billion annualized doses, once all capacity is brought online by mid-2021
Novavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in the United Kingdom in partnership with the government's Vaccines Taskforce, sending the company's shares up 6% after the bell.
The study is expected to enroll up to 10,000 participants aged between 18 and 84 years and comes after the vaccine candidate produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial.
Meanwhile, Britain recorded its highest number of daily cases of COVID-19 on Thursday at 6,634, reflecting a second wave of infections sweeping through the country but also a much higher level of testing than during the first wave.
Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
Never miss a story! Stay connected and informed with Mint.
our App Now!!